document incorporate reference table part portion registrant annual report shareholder fiscal year annual report iii portion registrant proxy statement annual meeting proxy statement table table caption item business general segment business consumer pharmaceutical medical device diagnostic geographic area raw material patent trademark seasonality competition research environment regulation available information property legal proceeding submission matter vote security holder executive officer registrant market registrant common equity relate stockholder matter select financial datum management discussion analysis result operation financial condition subsequent event quantitative qualitative disclosure market risk financial statement supplementary data change disagreement account financial disclosure control procedure iii director executive officer registrant executive compensation security ownership certain beneficial owner management certain relationship relate transaction principal accountant fee service exhibit financial statement schedule report form signature report independent auditor financial statement schedule exhibit index table item business general johnson johnson employ approximately people worldwide engage manufacture sale broad range product health care field operate company conduct business virtually country world johnson johnson primary interest historically currently product relate human health wellbee johnson johnson organize state new jersey johnson johnson organized principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate segment business johnson johnson worldwide business divide segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment operate result management discussion analysis result operation financial condition page johnson johnson annual report shareholder fiscal year annual report file exhibit report consumer consumer segment manufacture market broad range product baby child care skin care oral wound care woman health care field nutritional overthecounter pharmaceutical product major brand include aveeno skin care product bandaid brand adhesive bandage carefree panty shield clean clear teen skin care product johnson baby line product motrin ibuprofen product pepcid acid controller johnson johnson merck consumer pharmaceutical neutrogena skin hair care product splenda calorie sweetener stayfree sanitary protection product broad family tylenol acetaminophen product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical pharmaceutical segment principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology field product distribute directly wholesaler health care professional use prescription general public key product pharmaceutical segment include procrit epoetin alfa sell outside eprex biotechnology derive product stimulate red blood cell production duragesic fentanyl transdermal system sell abroad durogesic atreatment chronic pain offer novel delivery system risperdal risperidone risperdal consta risperidone longacte injection treatment symptom schizophrenia remicade infliximab novel monoclonal antibody therapy indicate treat symptom crohn disease rheumatoid arthritis levaquin levofloxacin floxin ofloxacin antiinfective field topamax topiramate antiepileptic ortho evra norelgestrominethinyl estradiol transdermal system contraceptive patch approve food drug administration fda doxil doxorubicin anticancer treatment ditropan oxybutynin chloride treatment overactive bladder reminyl galantamine patient mild moderate alzheimer disease natrecor nesiritide novel agent approve congestive heart failure medical device diagnostic medical device diagnostic segment include broad range product direction physician nurse therapist hospital diagnostic laboratory clinic product include ethicon wound care woman health product ethicon endosurgery minimally invasive surgical product cordis circulatory disease management product lifescan blood glucose monitoring product orthoclinical diagnostic professional diagnostic product depuy orthopaedic joint reconstruction spinal product vistakon disposable contact lense distribution health care professional market directly surgical supply dealer geographic area international business johnson johnson conduct subsidiary locate country outside united states sell product virtually country world product sell international business include describe business consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad investment activity country outside united states subject high risk comparable activity investment commercial climate influence restrictive economic policy political uncertainty raw material raw material essential johnson johnson operate company business generally readily available multiple source patent trademark johnson johnson practice obtain patent protection product process possible johnson johnson own license number patent relate product manufacturing process aggregate believe material importance operation business sale procrit risperdal account johnson johnson total revenue accordingly patent relate product believe material relation johnson johnson year eprex duragesic certain contraceptive product lose basic patent protection subject generic competition expiration product patent typically result loss market exclusivity result significant reduction sale sale product account approximately johnson johnson annual worldwide sale johnson johnson practice sell product trademark obtain protection trademark available mean johnson johnson trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research grantscompetition product line johnson johnson company compete company large small locate united states abroad competition strong line regard number size compete company involve competition research involve development new product process improvement exist product process particularly significant result time time product process obsolescence development new improved product important johnson johnson success area business competitive environment require substantial investment continue research multiple sale force addition win retention customer acceptance product johnson johnson consumer business involve heavy expenditure advertising promotion sell research research activity important segment johnson johnson business major research facility locate united states australia belgium brazil canada germany switzerland united kingdom cost johnson johnson worldwide research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer amount million fiscal year respectively cost charge directly income year incur research sponsor johnson johnson environment past year johnson johnson companies subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement expect material effect capital expenditure earning competitive position regulation johnson johnson business subject vary degree governmental regulation country operation conduct general trend regulation increase stringency united states drug device diagnostic cosmetic industry long subject regulation federal state local agency primarily product safety efficacy advertising labeling exercise broad regulatory power food drug administration fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend product process regulation evident number major country outside united states especially european economic community effort continue harmonize internal regulatory system cost human health care continue subject study investigation regulation governmental agency legislative body united states countries united states attention focus drug price profit program encourage doctor write prescription particular drug recommend particular medical device manage care potent force market place likely increase attention pay drug medical device price appropriate drug medical device utilization quality health care uncertainty impact medicare prescription drug improvement modernization act enact regulatory agency purview johnson johnson operate administrative power subject johnson johnson action product recall seizure product civil criminal sanction case johnson johnson deem advisable initiate product recall voluntarily addition sale marketing practice health care industry come increase scrutiny government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty available information copy johnson johnson quarterly report form annual report current report form amendment forego provide charge shareholder submit write request secretary principal executive office company call company sec filing available company website wwwinvestorjnjcomgovernance soon reasonably practicable electronically file furnished sec addition charter audit committee compensation benefit committee nominate corporate governance committee board director company principle corporate governance policy business conduct code business conduct ethic director executive officer available website address provide charge shareholder submit write request provide item property johnson johnson worldwide subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment johnson johnson business approximately follow table caption square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total table united states facility consumer segment pharmaceutical segment medical device diagnostic segment johnson johnson manufacturing operation outside united states conduct facility serve segment business location manufacture facility major geographic area world follow table caption number square feet geographic area facility thousands united states europe western hemisphere exclude usa africa asia pacific worldwide total table addition manufacturing facility discuss johnson johnson maintain numerous office warehouse facility world research facility discuss item business research johnson johnson generally seek manufacture facility principally location abroad lease office warehouse facility lease johnson johnson property maintain good operating condition repair utilize information lease obligation note rental expense lease commitment note consolidated financial statement annual report file exhibit report segmentinformation addition johnson johnson property plant equipment contain annual report file exhibit report item legal proceeding information set forth note legal proceeding note consolidated financial statement annual report incorporate reference file exhibit report form company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company item submission matter vote security holder applicable executive officer registrant list executive officer johnson johnson march indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include follow executive officer director incorporate reference page johnson johnson proxy statement date march proxy statement table caption age position robert darretta vice chairman board directors member executive committee chief financial officer russell deyo member executive committee vice president administrationa michael dormer member executive committee worldwide chairman medical devicesb roger fine member executive committee vice president general counselc colleen goggin member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officere brian perkin member executive committee worldwide chairman consumer pharmaceutical nutritional groupf peterson phd member executive committee chairman pharmaceutical research developmentg christine poon member executive committee worldwide chairman medicine nutritionalsh nicholas valeriani member executive committee vice president human resource worldwide chairman diagnosticsi table table caption age position william weldon chairman board directors chief executiveofficer chairman executive committee table deyo join company associate general counsel member executive committee vice president administration deyo vice president general counsel april dormer join company company group chairman worldwide franchise chairman depuy codman company acquire depuy inc time acquisition chief operating officer depuy inc dormer serve president depuy international ltd dormer member executive committee franchise group chairman medical devices april dormer name worldwide chairman medical device group fine join company member executive committee vice president administration vice president general counsel fine retire april goggins join company hold position president personal product company name president johnson johnson consumer product company company group chairman north america johnson johnson consumer product goggin member executive committee worldwide chairman consumer personal care group heisen join company treasurer controller member executive committee vice president chief information officer perkin join company hold position president mcneil consumer product company company group chairman otc pharmaceutical member executive committee worldwide chairman consumer pharmaceutical nutritional group peterson join company vice president drug discovery johnson pharmaceutical research institute name group vice president pharmaceutical research institute april president november peterson name chairman pharmaceuticals research development peterson member executive committee poon join company company group chairman pharmaceuticals group poon member executive committee worldwide chairman pharmaceutical group name worldwide chairman medicine nutritional prior join company serve management position bristolmyer squibb year recently president international medicine president medical devices valeriani join company hold position president ethicon endosurgery inc january name company group chairman ethicon endosurgery additional responsibility johnson johnson medical product medical device diagnostic business canada worldwide franchise chairman depuy franchise valeriani member executive committee vice president human resource september february assume additional responsibility worldwide chairman diagnostic item market registrant common equity relate stockholder matter march approximately record holder common stock company information call item incorporate reference material caption management discussion analysis result operation financial condition share repurchase dividend common stock market price note note consolidated financial statement annual report file exhibit report item select financial datum information call item incorporate reference material caption summary operation statistical datum annual report file exhibit report form item management discussion analysis result operation financial condition information call item incorporate reference narrative tabular graphic material include material caption management discussion analysis result operation financial condition page annual report file exhibit report subsequent event february company cordis operate company announce enter strategic alliance guidant corporation copromotion drugelute stent advancement new technology coronary stent delivery system sale marketing resource company join force focus promote cypher sirolimuselute coronary stent united states option pursue similar arrangement japan future company collaborate marketing sale strategy associate cypher stent bear marketing sale cost separately cordis continue report cypher stent sale revenue cordis obtain access guidant current generation technology delivery coronary stent guidant cordis immediately initiate development regulatory plan cypher stent utilize guidant stent delivery system addition outstanding patent dispute company settle describe note legal proceeding note consolidated financial statement file exhibit report item quantitative qualitative disclosure market risk information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource page annual report file exhibit report form item financial statement supplementary datum consolidated financial statement note thereto material caption report independent auditor incorporate reference page annual report file exhibit report item change disagreement accountant account financial disclosure applicable item control procedure disclosure control end fiscal fourth quarter company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure company record process summarize report timely manner information company disclose report file securities exchange act william weldon chairman chief executive officer robert darretta vice chairman chief financial officer review participate evaluation base evaluation messr weldon darretta conclude date evaluation company disclosure control procedure effective internal control fiscal quarter end december significant change company internal control financial reporting materially affect reasonably likely materially affect company internal control iiiitem director executive officer registrant information call item incorporate reference material caption election director nominee page proxy statement material hereof caption executive officer registrant discussion audit committee head director fee committee meeting page proxy statement material caption section beneficial ownership report compliance proxy statement company policy business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act policy business conduct available company website wwwjnjcom copy policy business conduct available shareholder charge write request secretary company principal address substantive amendment policy business conduct waiver policy grant chief executive officer chief financial officer controller post company website wwwjnjcom business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic director executive officer available company website wwwjnjcom copies code business conduct ethic available shareholder charge write request secretary company principal address substantive amendment code waiver code grant member board director executive officer post company website wwwjnjcom business day retain website year item executive compensation information call item incorporate reference follow section proxy statement election director director fee committee meeting page compensation benefit committee report executive compensation page shareholder return performance graph page executive compensation page item security ownership certain beneficial owner management information call item incorporate reference material caption election director stock ownershipcontrol page proxy statement note note consolidated financial statement annual report file exhibit report item certain relationship relate transaction applicable item principal accountant fee service information call item incorporate reference material heading appointment independent auditor preapproval audit nonaudit service page proxy statement item exhibit financial statement schedule report form follow document file report financial statement follow consolidated financial statement note thereto independent auditor report page annual report shareholder fiscal year incorporate reference file exhibit report consolidated balance sheet end fiscal year consolidated statement earning fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent auditor financial statement schedule schedule valuation qualifying account schedule list omit require applicable exhibit require file item regulation information call item incorporate reference exhibit index report report form report form furnish january include press release announce decision james lenehan retire company june resign vice chairman board directors president effective february report form furnish january include press release date january announce company sale earning fourth quarter fiscal year end december include consolidated financial result report form furnish march include press release announce company cordis subsidiary enter strategic alliance guidant corporation respect cypher drugelute stent report form file march include management discussion analysis financial condition result operation audit consolidated financial statement note thereto report independent auditor december johnson johnson subsidiaries schedule valuation qualifying account fiscal year end december december december dollar million table caption addition balance charge deduction reserve balance begin cost end period expensesa description period reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment table charge relate customer rebate cash discount reflect reduction sale customer signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date march johnson johnson registrant weldon weldon chairman board directors chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate table caption signature title date weldon chairman board director march chief executive officer weldon director principal executive officer darretta vice chairman board director march chief financial officer director darretta principal financial officer cosgrove controller march cosgrove burrow director march burrow coleman director march coleman cullen director march cullen folkman director march folkman jordan director march jordan langbo director march langbo table table caption signature title date lindquist director march lindquist mullin director march mullin reinemund director march reinemund satcher director march satcher schacht director march schacht table report independent auditor financial statement schedule shareholder board directors johnson johnson audits consolidated financial statement refer report date january fifth thirteenth paragraph note date february february respectively appear annual report shareholder johnson johnson report consolidated financial statement incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp pricewaterhousecooper llpnew york new york january exhibit index table caption reg exhibit table description item exhibit restate certificate incorporation date april incorporate reference exhibit registrant annual report year end december aii certificate amendment restate certificate incorporation company date incorporate reference exhibit registrant annual report year end january aiii certificate amendment restate certificate incorporation company date incorporate reference exhibit aiii registrant annual report year end december aiv certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form quarterly report quarter end july bylaw company amend effective june incorporate reference exhibit registrant form quarterly report quarter end july request security exchange commission registrant furnish copy instrument define right holder long term debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december stock option plan amend incorporate reference exhibit registrant annual report year end december stock option plan amend incorporate reference exhibit registrant annual report year end january stock option plan amend incorporate reference exhibit registrant annual report year end december stock compensation plan incorporate reference exhibit registrant annual report year end december executive incentive plan amend incorporate reference exhibit registrant annual report year end december domestic deferred compensation certificate extra compensation plan amend file document defer fee plan director amend incorporate reference exhibit registrant annual report year end december executive income deferral plan amend file document excess saving plan incorporate reference exhibit registrant annual report year end december supplemental retirement plan incorporate reference exhibit registrant annual report year end january executive life insurance plan incorporate reference exhibit registrant annual report year end january stock option gain deferral plan incorporate reference exhibit registrant form kannual report year end january table table caption reg exhibit table description item exhibit estate preservation plan incorporate reference exhibit registrant annual report year end january letter agreement date june company larsen respect postemployment arrangement incorporate reference exhibit registrant annual report year end december consulting agreement company judah folkman member board incorporate reference exhibit registrant annual report year end december statement computation ratio earning fix charge file document page company annual report shareholder fiscal year portion annual report incorporate reference report deem file file document subsidiary file document consent independent accountant file document certification chief executive officer rule securities exchange act pursuant section sarbanesoxley act file document certification chief financial officer rule securities exchange act pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document certification chief financial officer pursuant section sarbanesoxley act furnish document annual report form johnson johnson saving plan file june cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document table management contract compensatory plan arrangement require file exhibit form pursuant item report form copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive office company text document document typeexg sequence filenameyexvwgtxt descriptiondomestic defer compensation plan text exhibit johnson johnson certificate extra compensation planwitnesseth johnson johnson company wish reward employee employee subsidiarie employee faithful service past particularly encourage employee future work permit employee share growth success company enterprise issue share certificate extra compensation cec share end receive extra compensation sum base measure cash dividend time time declare equal number share common stock company common stock formula value cec share establish pursuant article ninth plan formula value time termination employment death employment consideration premise promise contain long employee shall remain employee agree number cec share designate employee extra compensation shall base aggregate number cec share award employee accordance plan evidence write record company second employee remain employee company shall pay employee date pay cash dividend company common stock sum equivalent cash dividend multiply total number cec share designate employee employee employee record date dividend event employee death employee company shall pay employee beneficiary record employee signature record company sum money shall determined percentage formula value cec share percentage shall base period elapse date cec share award death follow event death eighteen month date award event death eighteen month fortytwo month date award event death fortytwo month date award event termination employee employment retirement physical mental disability reason death company shall pay employee sum money shall determined percentage formula value cec share purpose plan term retirement shall mean termination employment follow employee entitlement normal retirement early retirement benefit consolidate retirement plan johnson johnson successor pursuant term plan effect date employee terminate employment purpose plan employee place longterm disability consider employee percentage shall base period elapse date cec share award termination employment follow event termination month date award event termination month twentyfour month date award event termination twentyfour month thirtysix month date award event termination thirtysix month fortyeight month date award event termination fortyeight month month date award event termination month date award company shall pay sum money article single lump sum employee timely deferral electionpursuant provision article seventh defer receipt sum hisher retirement retire pursuant definition retirement article fourth election employee provide payment sum employee hisher retirement defer pay single lump sum installment lump sum payment defer taxable year follow employee retirement date installment payment elect installment payment immediately retirement defer taxable year installment payment annually manner describe approximately equal installment amount value cec payout balance plus accrued interest divide number remain installment minimum number annual installment maximum number employee elect defer value hisher total cec holdings retirement percentage increment follow rule shall apply respect payment immediate lump sum payment employee receive value hisher cec holdings calendar month hisher retirement effective date employee retire prior determination prior year cec value receive estimate value remainder pay shortly final value determine defer lump sum payment employee receive value hisher cec holding plus accrued interest january year heshe elect receive payment immediate commencement installment employee receive installment calendar month hisher retirement effective date subsequent installment plus accrue interest pay january year defer commencement installment employee receive subsequent installment plus accrue interest january year fifth respect portion formula value employee cec holdings hisher retirement date defer andor pay installment interest shall pay company effective date retirement date payment interest rate defer amount shall fix employee date retirement interest rate shall determine treasurer company sole discretion base yield curve activelytrade united states government debt date retirement period comparable length period deferral installmentsthe rate shall round decimal place interest shall compound semiannually calendar day june december year establish interest rate shall remain fix period deferral sixth event death employee prior termination hisher employment company payment balance plus accrued interest soon administratively practical single lump sum payment designate beneficiary seventh election employee defer payment elect installment formula value hisher cec holdings hisher retirement date hisher effective retirement date minimum month prior date retirement date election revise revoke month prior retirement date month period prior retirement date election irrevocable revoke revise company disallow employee desire defer payment andor elect installment determine participation jeopardize plan compliance applicable law plan status hat plan erisa election defer payment andor pay installment effective file administrator refer article fifteenth form utilize purpose election require deadline shall disregard election defer andor pay installment consultation employee tax andor financial advisor eighth number cec share designate base measured extra compensation employee shall increasedproportionately time time extent stock split dividend common stock declare pay issue outstanding common stock company likewise number cec share shall reduce proportionately time time extent number cec share issue outstanding common stock company reduce reorganization reduction capital ninth purpose article agreement formula value cec share shall determine company board director shall event mention determine formula value sum onehalf asset value share common stock plus onehalf earningpower value share common stock calculate follow sum onehalf consolidated net asset value share common stock asset share liability include reserve surplus reserve share asset liability appear book company subsidiary fiscal year end immediately precede date valuation plus onehalf consolidated earningpower value share common stock determine average annual net earning share common stock taxis net earning appear book company subsidiary fiscal year precede date valuation capitalize return capital invest percent multiple onehalf time average earning share purpose forego calculation book company subsidiary shall conclusive method consolidation shall adopt company prepare previous annual report stockholder include appropriate provision taxis foreign domestic incur remit income subsidiary company decision company treasurer time time time procedure adopt maintain book company subsidiary preparation balance sheet income statement method adjustment consolidation matter accounting practice procedure shall conclusive event shall opinion board director company calculation provide result true value date article determination necessary board sole discretion shall obligate vary formula formula value cec share determine board director shall fifteenth year determine announce formula value cec share immediately precede fiscal year end purpose plan tenth dividend share value measure extra compensation pay hereunder contain shall construe agreement transfer employee hisher beneficiary shall acquire virtue hisher award cec share right title interest whatsoever company common stock eleventh right benefit cec share award plan assignable company fund obligation create employee participation cec plan company make unsecured promise pay obligation general corporate asset apply obligation active retire participant certificate represent cec share issue instead number cec share award shall record book company twelfth regular parttime employee work hour week shall consider employee plan change parttime status hour week shall consider termination provide event employee age employee shall purpose plan deem elect retirement define article contain plan shall construe alter present employment indefinite term terminable employee company prior advance notice thirteenth employee leave company subsidiary request company work joint venture operation company subsidiary minority partnership interest sole discretion management compensation committee consider employee solely purpose plan period year follow departure company arrangement extended additional year management compensationcommittee sole discretion determine good interest company person cease employment joint venture operation concomitant return employment company subsidiary person shall immediately consider terminate cease consider employee purpose plan fourteenth employee designate beneficiary receive value hisher payout death beneficiary predecease employee beneficiary name designate beneficiary employee payout balance case distribute employee estate beneficiary designation revise time submit beneficiary designation form administrator set forth article sixteenth beneficiary beneficiary indicate form shall supersede prior designation fifteenth quarter calendar year statement send active employee participate cec plan retiree defer cec holding report active employee provide value cec holding base prior year final cec value statement include previously deferral election beneficiary designation report retiree provide defer cec payout balance plus interest defer andor installment election beneficiary designation sixteenth cec plan administer extra compensation services department corporate headquarters company question regard administration cec plan address board director discretion shall authority terminate amend plan cancel amend term cec share grant hereunder necessity obtain approval employee hold cec share termination cancellation amendment shall effect reduce dollar value vest cec share pay defer aggregate formula value fiscal year end immediately precede termination cancellation amendment increase vest period article cec share delay payment payment cec share holder event termination plan cancellation cec share grant hereunder company shall pay employee sum money shall determine accordance provision article relate termination employment retirement physical mental disability reason death payment provision shall single lump sum day termination cancellation text document document typeexi sequence filenameyexvwitxt descriptionexecutive income deferral plan amend text exhibit johnson johnson executive income deferral plan johnson johnson executive income deferral plan plan intend permit select group executive defer income immediately payable compensation andor incentive plan johnson johnson company administration plan administer compensation committee company board director committee shall responsibility determine investment time time available plan shall review investment option year committee shall decision affect timing price defer award hereinafter define participant subject section security exchange act amend delegate authority plan eligibility eligibility defer income amount plan initially limit members executive committee thecompany committee time time expand eligibility defer compensation plan executive company committee authority refuse permit executive participate plan elect defer payment committee determine participation jeopardize plan compliance applicable law plan status hat plan erisa deferral income deferral account estate preservation plan participant elect defer percent annual salary percent cash andor stock awards company executive incentive plan iii percent dividend equivalent pay company certificate extra compensation cec plan percent dividend equivalent pay deferred gain share company stock option gain deferral plan amount defer know deferred award direct election participant income deferral account estate preservation plan describe participant decision defer plan september year prior commencement fiscal year compensation bonus incentive payment dividend equivalent monie defer earn notwithstanding forego require notice period election respect amount defer shall govern notice election provision stock option gain deferral plan election defer pursuant section shall effective timely file extra compensation service form utilize purpose participant shall designate multiple defer award portion allocate investment option available plan participant change investment option defer award credit income deferral account month change effective day month follow month participant request change allocation file extra compensation service determine maximum amount defer participant plan committee shall account include commitment participant estate preservation plan extent salary andor cash award company executive incentive plan insufficient meet prior deferral commitment participant plan estate preservation plan deferral commitment plan shall reduce accordingly deferral commitment estate preservation plan fund election defer dividend equivalent company cec plan apply election apply cec contract reverse order issuance defer award shall hold account regardless form compensation plan earn cease employee company participant event participant death name beneficiary hisher estate shall entitle receive cash lump sum value hisher income deferral account date termination participant elect pursuant provision section defer payment hisher income deferral account retirement notwithstanding participant fiscal year name executive officer proxy statement report purpose reason hisher chief executive officer company high compensate officer chief executive officer payment income deferral account year shall postpone date day january follow fiscal year provide fund income deferral account shall deemed invest year treasury bill rate describe date retirement payment investment income deferral account election participant amount income deferral account invest utilize investment option set forth amount defer month include stock award value credit participant income deferral account effective day month amount defer estate preservation plan separate distinct amount defer income deferral account common stock equivalent unit amount elect deferred investment option shall convert equivalent unit company common stock common stock compensation defer invest common stock common stock equivalent unit defer award stock awards company executive incentive plan number common stock equivalent unit shall determine bydividing compensation dividend equivalent defer average high low price common stock trade new york stock exchange trading day immediately precede trading day month report bloomberg financial reporting service select company sole discretion company shall credit participant income deferral account effective trading month number partial share company common stock determine defer award represent stock award company executive incentive plan number common stock equivalent unit shall determine dividing compensation issue stock award average high low price common stock trade new york stock exchange trading day compensation committee board director approve stock award executive incentive plan report bloomberg financial reporting service select company sole discretion company shall credit participant income deferral account effective date number partial share company common stock determine notwithstanding forego time shall share company common stock actually purchase earmark income deferral account participant shall right shareowner respect share credit income deferral account number common stock equivalent unit include participant income deferral account shall adjust reflect payment dividend increase decrease market value resulted fund equal defer actually invest common stock value company common stock purpose investment redesignation describe section shall closing price company common stock new york stock exchange trading day immediately precede trading day month participant redesignation request receive extra compensation service report determined shall effective trading day month distributions cash value equivalent share company common stock value closing price company common stock new york stock exchange trading date precede distribution date report determined event reorganization stock split stock dividend combination share merger consolidation right offering change corporate structure share company committee shall adjustment deem appropriate number kind share company common stock credit participant income deferral account balanced fund amount elect deferred option shall deem invest credit investment rate return earn balanced fund option company saving plan successor fund balanced fund share shall purchase earmarked participant account year treasury bill rate amount elect deferred option shall deem invest interest bear account bear interest year treasury bill rate compound monthly purpose plan year treasury bill rate shall interest rate year treasury bill trading day precede calendar year provide financial reporting service shall select company sole discretion rate shall adjust annually treasury bill actually purchase earmark participant account redesignation investment option income deferral account participant redesignate amount previously credit income deferral account investment option available plan participant wish redesignate particular investment option time redesignate investment option redesignation investment place day prior schedule distribution plan follow additional rule shall apply respect redesignation previously creditedamount permit frequencyredesignation participant consecutive month period extent redesignationredesignation participant multiple investment redesignation timingredesignation shall place effective day month follow month participant write redesignation receive extra compensation service value company common stock purpose investment redesignation shall average high low trading price common stock new york stock exchange report determined trading day immediately precede trading day prior month special rule redesignation common stock equivalent unit previously credit income deferral account material nonpublic informationthe committee sole discretion advice counsel time rescind redesignation common stock equivalent unit redesignation participant time redesignation possession material nonpublic information respect company committee estimation benefit information timing redesignation committee determination shall final bind event rescission participant income deferral account shall return status redesignation occur notwithstanding committee shall rescind redesignation fact review participant general counsel company designee prior redesignation general counsel designee conclude participant possession material nonpublic information participant subject section securities exchange act redesignate income deferral account common stock equivalent unit applicable window period respect release quarterly annual statement sale earning company iii redesignation amount income deferral account shall common stock equivalent unit month discretionary opposite way transaction common stock hold participant company saving plan estate preservation plan participant transfer amount income deferral account balance estate preservation plan accordance term estate preservation plan transfer estate preservation plan amount transfer income deferral account distribution income deferral account participant employment terminate reason include death disability participant eligible retire active service company pension plan income deferral account automatically pay lump sum soon administratively feasible month follow termination employment distribution cash value equivalent share company common stock value average high low trading price common stock new york stock exchange report determined trading day immediately precede trading day month employment terminate post retirement deferral election participant provide payment sum participant hisher retirement deferred pay single lump sum installment lump sum payment defer taxable year follow participant retirement date installment payment elect installment payment immediately retirement defer taxable year installment payment annually manner describe approximately equal installment amount value balance income deferral account plus accrue interest divide number remain installment minimum number annual installment maximum number participant elect defer value hisher total income deferral account retirement percentage increment payment amount income deferral account pursuant section shall subject provision sentence section follow additional rule shall apply respect payment immediate lump sum payment participant receive value income deferral account calendar month retirement effective date participant retire prior determination prior year incentive plan award receive estimate value remainder pay shortly final value determine defer lump sum payment participant receive value income deferral account plus accrue interest january year elect receive payment immediate commencement installments participant receive installment calendar month hisher retirement effective date subject provision sentence section subsequent installment plus accrue interest pay january year defer commencement installment participant receive subsequent installment plus accrue interest january year respect amount defer andor pay installment interest shall pay company effective date retirement date payment interest rate defer andor installment payment participant shall fix date retirement shall rate rounded decimal place offer report financial reporting service company sole discretion shall select effective retirement date united states treasury instrument period comparable length period deferral andor installment payment interest shall compound semiannually calendar day june december year instrument quote average rate shall utilize way example election receive installment year comparable year treasury rate shall utilize election defer commencement installment year installment pay year comparable year treasury rate shall utilize established interest rate shall remain fix period deferral andor installment event death participant follow retirement company payment balance hisher income deferral account plus accrue interest soon administratively practical single lump sum payment designate beneficiary subject provision sentence section event deferral installment election section total income deferral account pay accordance provision section lump sum payment soon practical follow participant retirement effective date election participant defer payment elect installment hisher account hisher effective retirement date minimum month prior date retirement date election revise revoke month prior retirement date month period prior retirement date election irrevocable revoked revise notwithstanding plan inception exception participant retirement effective date january december participants retirement effective date prior june deferral andor installment election minimum month calendar year prior retirement date participant retirement date july december election month prior retirement date example participant retire april deferral andor installment election later december retirement date august election later january election defer andor receive installment payment revise revoke prior lastpermissible date make election time election revoke revise election defer payment andor pay installment effective timely file extra compensation service form utilize purpose election require deadline shall disregard estate preservation plan describe section participant elect transfer portion balance income deferral account estate preservation plan accordance term estate preservation plan event election participant income deferral account shall reduce direct participant december year transfer occur transfer income deferral account estate preservation plan shall effective december year transfer shall irrevocable pursuant term split dollar life insurance agreement designate compensation committee term condition set compensation committee election participant transfer amount income deferral account estate preservation plan participant shall deemed waive irrevocably right benefit plan respect amount transfer addition term set forth paragraph amount participant income deferral account transfer estate preservation plan order satisfy prior obligation participant connection estate preservation plan transfer shall solely direction compensation committee determination compensation committee transfer necessary shall effect term condition voluntary transfer paragraph determine committee transfer necessary participant income deferral account shall reduce requisite december year direct compensation committee determination compensation committee subsequent transfer amount estate preservation plan participant shall deem waive irrevocably right benefit plan respect amount transfer deduction distribution company deduct distribution amount require withhold income social security tax purpose withholding pro rata basis investment company deduct amount participant owe company reason beneficiary designation participant designate beneficiary receive value hisher income deferral account death beneficiary predecease participant beneficiary name designate beneficiary participant balance case distribute participant estate beneficiary designation revise time submit beneficiary designation form extra compensation service amendment committee amend plan time amendment shall consent participant materially adversely affect right obligation respect defer award theretofore miscellaneous company fund obligation create participant participation plan company make unsecured promise pay obligation general corporate asset apply obligation active retired participant quarter calendar year statement send active participant participate plan retiree deferral account statement include previously deferral election beneficiary designation report retiree provide deferred payout balance plus interest defer andor installment election beneficiary designation plan shall administer extra compensation services department corporate headquarters company question regard theadministration plan address election defer andor pay installment consultation participant tax andor financial advisor text document document typeex sequence filenameyexvtxt descriptionstatement computation ratio earning text exhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million table caption fiscal year end december december december december january determination earning earning provision taxis income fix charge total earning define fix charge rent interest fix charge capitalize interest total fix charge ratio earning fix charge table ratio earning fix charge represent historical ratio johnson johnson calculate total enterprise basis ratio compute dividing sum earning provision taxis fix charge exclude capitalize interest fix charge fix charge represent interest include capitalize interest amortization debt discount expense interest factor rental consist appropriate interest factor operating lease text document document typeex sequence filenameyexvtxt descriptionpage annual report shareholder text management discussion analysis result operation financial conditionorganization business segment description company business segment company subsidiary approximately employee worldwide engage manufacture sale broad range product health care field company conduct business virtually country world primary interest historically currently product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment manufacture market broad range product baby child care skin care oral wound care woman health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology area product distribute directly wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal product ethicon wound care woman health product ethicon endosurgery minimally invasive surgical product lifescan blood glucose monitoring product orthoclinical diagnostic product vistakon disposable contact lense company structure base principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate product line company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant periodically result product process obsolescence development new improve product important company success area business competitive environment require substantial investment continue research multiple sale force addition win retention customer acceptance company consumer product involve significant expenditure advertising promotion management objective company objective achieve superior level capital efficient profitable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth segment development innovative product service billion sale invest research development recognize importance ongoing development new differentiate product service operate company locate country company view principle decentralize management asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability react quickly local market change challenge business manage long term order sustain leadership position achieve growth provide endure source value shareholder unify management team company dedicated employee achieve objective johnson johnson credo credo provide common set value serve constant reminder company responsibility customer employee communitie shareholder company believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry company continue evaluate enhance exist internal control process evaluate implement internal control reporting requirement sarbanesoxley act company recognizesthat rely depend leadership management team johnson johnson family company ensure successful compliance sarbanesoxley act additionally company continue maintain strong ethical environment johnson johnson credo overall guide result operation analysis consolidate sale worldwide sale increase billion compare increase sale increase consist follow table caption sale increase volume price currency total table sale company billion billion billion represents increase sale international company billion billion billion represent increase graph year annual compound growth rate worldwide international sale respectively tenyear annual compound growth rate worldwide international sale respectively graph geographic area world post doubledigit sale increase sale increase europe western hemisphere exclude asiapacific africa region sale gain include positive impact currency fluctuation dollar foreign currency europe asiapacific africa region negative impact currency fluctuation western hemisphere exclude sale distributor mckesson hboc amerisourcebergen corp cardinal distribution account respectively total revenue amerisourcebergen corp account total revenue mckesson hboc cardinal distribution accounting revenue respectively graph analysis sale business segment consumer consumer segment sale billion increase operational growth accounting total growth currency fluctuation consumer segment sale billion increase international sale billion increase operation currency fluctuation consumer segment sale growth attributable strong sale performance major franchise segment include skin care baby kid care mcneil consumer overthecounter pharmaceutical nutritional product skin care franchise sale billion represent increase growth attribute solid sale neutrogena brand product especially international market aveeno brand product facial care line new product launch half baby kid care franchise grow billion growth franchise lead new product launch include johnson softwash johnson softlotion mcneil consumer overthecounter pharmaceutical nutritional product sale billion increase contribute growth continue growth splenda brand calorie sweetener increase salesin motrin tylenol brand product early strong cold flu season franchise contribute overall sale growth consumer segment woman health franchise achieve sale billion increase strong growth sanitary protection product international market contribute growth franchise consumer segment sale billion increase increase operational growth offset negative currency impact sale increase international sale gain operational gain offset negative currency impact consumer segment sale billion increase increase operational growth offset negative currency impact sale increase international sale gain sale gain local currency offset negative currency impact pharmaceutical pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency pharmaceutical segment sale increase international pharmaceutical segment sale increase include growth operationally relate positive impact currency sale billion table caption change million dollar procriteprex epoetin alfa risperdal risperidone remicade infliximab duragesic fentanyl transdermal system hormonal contraceptive levaquinfloxin levofloxacin ofloxacin topamax topiramate table pharmaceutical segment sale growth reflect strong performance key pharmaceutical product despite sale decline procrit epoetin alfa eprex epoetin alfa adversely affect competition label change combine procrit eprex sale decline compare decline net effect strong market growth positive currency impact offset loss market share company continue implement program improve competitive position include step ensure procrit price competitively conduct clinical development program provide comparative datum competitive product strong growth driver pharmaceutical segment duragesic fentanyl transdermal system sell outside durogesic novel delivery system treatment chronic pain continue achieve outstanding result grow year currently litigation challenge patent exclusivity duragesic impact sale product event product expect face generic competition january note discussion matter psychotropic central nervous system field risperdal risperidone medication treat symptom schizophrenia account billion sale fuel successful launch risperdal consta risperidone longacte injection market outside united states october product approve food drug administration fda remicade infliximab novel monoclonal antibody therapy indicate treat symptom crohn disease rheumatoid arthritis autoimmune disorder account billion sale continue maintain leadership position grow autoimmune market antiinfective field include levaquin levofloxacin floxin ofloxacin strong growth hormonal contraceptive franchise grew fuel ortho evra norelgestrominethinylestradiol contraceptive patch approve fda strong growth brand include doxil doxorubicin anticancer treatment ditropan oxybutynin treatment overactive bladder reminyl galantamine hbr treatment patient mild moderate alzheimer disease acquisition scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease contribute pharmaceutical segment sale growth scio acquire strengthen company business key therapeutic area technology platform scio product natrecor nesiritide novel agent approve congestive heart failure significant advantage exist therapy pharmaceutical segment sale billion increase operation growth currency fluctuation sale increase international sale grow include positive impact currency operational growth pharmaceutical segment sale billion total increase sale increase international sale increase operational growth offset negative currency impact medical device diagnostic worldwide medical device diagnostic segment achieve sale billion represent increase prior year operational growth positive impact currency sale increase international sale increase operation currency strong sale growth segment lead cordis depuy franchises cordis franchise key contributor medical device diagnostic segment result report sale billion signifie growth prior year primary driver sale growth cypher sirolimuselute stent approve fda april device treatment coronary artery disease implant approximately half million patient world cypher drugelute stent approve use product pende approval fda compete cypher sirolimuselute stent depuy franchise report billion sale represent growth prior year depuy orthopaedic joint reconstruction product include shoulder knee product line primarily responsible growth global advantage system shoulder market continue trend mobile bearing minimally invasive unicompartmental knee strong performance report area spinal orthobiologic lead continued success new product sale acquisition orqu principal product healos bone graft substitute design enhance fusion franchise contribute overall sale growth medical device diagnostic segment include ethicon ethicon endosurgery lifescan orthoclinical diagnostic vision care franchise ethicon worldwide franchise report billion sale growth rate prior year ethicon franchise continue grow introduce new product marketplace coat vicryl polyglactin plus product new antibacterial suture platform ethicon endosurgery franchise report billion sale growth rate prior year growth mainly drive endocutter sale include product perform bariatric procedure treatment obesity important focus area ethicon endosurgery lifescan franchise report billion sale growth rate prior year september lifescan launch upgrade onetouch basic test strip require blood insulin test orthoclinical diagnostic franchise report billion sale growth rate prior year growth mainly drive launch vitros eci ahavtotal assay measurement antibody hepatitis virusthe vision care franchise report billion sale growth rate prior year lead continued success japanese market worldwide sale billion medical device diagnostic segment represent total increase total increase represent operational sale increase prior year sale international sale increase prior year worldwide sale billion medical device diagnostic segment represent total increase operational sale gain offset negative currency impact sale international sale increase operational sale gain offset negative currency impact analysis consolidate earning provision taxis income consolidated earning provision taxis income increase billion billion increase billion percent sale consolidated earning provision taxis income represent decline improvement improvement section follow highlight significant component change consolidated earning provision taxis income cost good sell sell marketing administrative expense cost good sell sell marketing administrative expense percent sale follow table caption sale cost good sell increasedecrease sell marketing administrative expense increasedecrease table improvement percent sale sell marketing administrative expense increase percent sale cost good sell change mix product vary cost structure cost retirement enhancement program million offer fourth quarter decrease attributable expense leverage sale increase productivity improvement research development research activity represent significant company business expenditure relate development new product improvement exist product technical support product compliance governmental regulation protection consumer worldwide cost research activity exclude inprocess research development charge follow table caption million dollar research expense percent increase prior year percent sale table research development expense percent sale pharmaceutical segment average consumer medical device diagnostic segment combine respectively significant research activity continue pharmaceutical segment increase billion compound annual growth rate approximately fiveyear period johnson johnson pharmaceutical research development llc operate separate unit janssen research foundation johnson pharmaceutical research institute primary worldwide pharmaceutical research organization additional research conduct centocor alza tibotecvirco scios inc collaboration james black foundation london england inprocess research development company record inprocess research development iprd charge million tax relate acquisition acquisition include scios inc link spine group inc certain assets orquest inc dimensional pharmaceuticals inc scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease acquisition scios inc account million tax iprd charge include operate profit pharmaceutical segment link spine group inc acquire provide company exclusive worldwide right charite artificial disc treatment spine disorder acquisition link spine group inc account million tax iprd charge include operate profit medical device diagnostic segment orquest inc biotechnology company focus develop biologicallybase implant orthopaedic spine surgery acquisition certain asset orquest inc account million tax iprd charge include operate profit medical device diagnostic segment dimensional pharmaceuticals inc company technology platform focus discovery development potential new drug early stage development inflammation acquisition dimensional pharmaceuticals inc account million tax iprd charge include operate profit pharmaceutical segment company record iprd charge million tax relate acquisition tibotecvirco privatelyheld biopharmaceutical company focus develop antiviral treatment obtech medical privately hold company market adjustable gastric band treatment morbid obesity iprd million million include pharmaceutical medical device diagnostic group respectively company record iprd charge million tax incur result acquisition inverness medical technology inc supplier lifescan electrochemical product blood glucose monitoring follow spinoff nondiabetes business terame inc early stage medical device company develop endovascular stentgraft system minimally invasive treatment abdominal aortic aneurysm total iprd million include medical device diagnostic segment income expense net income expense include gain loss relate sale writedown certain investment equity security hold johnson johnson development corporation gainslosse disposal fix asset currency gain loss minority interest litigation settlement income expense royalty income change net income expense net income million income expense include income arbitration ruling million relate stent patent receive fourth quarter include medical device diagnostic segment operating profit include medical device diagnostic segment operating profit gain sale product line long compatible segment strategic goal income expense include recovery million loan previously reserve include pharmaceutical segment operate profit income expense include gain sale ortho pref product line impact amgen arbitration settlement october arbitrator chicago deny effort amgen inc terminate license agreement ortho biotech inc obtain exclusive right amgendevelope erythropoetin epo indication outside kidney dialysis decision arbitrator find sale market amgen retain exclusive right warrant extraordinary remedy terminate contract instead find amgen adequately compensate monetary damage arbitrator award million damage january arbitrator rule amgen prevail party arbitration entitling award reasonable attorney fee cost company expense million fourth quarter connection claim charge include pharmaceutical segment operate profit addition item indicate income expense include cost relate merger alza million amortization expense approximately million long require financial accounting standard board fasb standard goodwill intangible asset sfas operating profit segment business follow table caption percent segment sale million dollar consumer pharmaceutical med devices diag segment total expense allocate segment earning provision taxis income table amount allocate segment include interest incomeexpense minority interest general corporate income expense graph consumer segment operate profit consumer segment percent sale remain unchanged expense leverage increase sale volume offset cost incur manufacturing program gain future efficiency advertising consumer segment operating profit increase prior year reflect operate profit percent sale improvement improvement primarily leverage selling promotion administrative expense offset increase expenditure advertising additionally consumer segment operating profit improve amortization expense goodwill certain trademark long require sfas pharmaceutical segment operating profit pharmaceutical segment percent sale reflect decline iprd charge relate acquisition previously note additionally operate profit impact sale decline high margin product procriteprex increase consumer promotional spend new product line extension pharmaceutical segment operating profit increase reflect operate profit percent sale improvement operating profit negatively impact cost amgen arbitration settlement million damage legal fee iprd related acquisition offset gain sale ortho prefest product line impact sfas operating profit percent sale operating profit include impact expense relate merger alza million medical device diagnostic operating profit medical device diagnostic segment percent sale reflect improvement increase sale volume primarily cypher stent sale driver medical device diagnostic segment growth medical device diagnostic segment operating profit increase reflect operating profit percent sale improvement nonamortization goodwill certain trademark account improvement remain margin improvement prior year achieve despite investment spending support cordis product line operating profit include iprd relate acquisition interest income expense interest income decrease million primarily basis point decrease average yield investment compare cash balance include current marketable security end billion average billion slightly high billion average cash balance interest expense increase million compare primarily increase average debt balance billion billion average interest rate outstanding debt decrease approximately basis point year year provision taxis income worldwide effective income tax rate increase effective tax rate year primarily company nondeductible iprd charge increase income subject tax refer note additional information liquidity capital resource cash flow cash generate operation select borrowing provide major source fund growth business include work capital capital expenditure acquisition share repurchase dividend debt repayment cash flow operation billion increase billion major factor contribute increase increase net income billion increase iprd billion increase account payable accrue liability billion primarily increase volume timing payment decrease pension funding billion change defer taxis billion detailed discussion change defer taxis note net cash investing activity increase billion acquisition detailed discussion merger acquisition note net cash financing activity decrease billion impact billion stock repurchase offset change net repayment debt billion financing activity increase decrease longterm shortterm debt financing acquisition scios inc company retire net billion commercial paper cash current marketable security billion end compare billion end graph cash generate operation amount billion cash generate operation billion decrease primarily fund pension plan approximately billion net current tax benefit contractual obligation commitment company longterm contractual obligation primarily lease debt obligation unfunded retirement plan satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity december note detail table caption unfunded operating debt retirement million dollar lease obligation plan table share repurchase dividend february company announce stock repurchase program billion time limit program program complete onaugust million share repurchase aggregate price billion addition company annual program repurchase share use employee stock employee incentive plan company increase dividend consecutive year cash dividend pay share compare dividend share share dividend distribute follow table caption quarter second quarter quarter fourth quarter total table january board director declare regular cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value exist foreign currency asset liability hedge future foreign currency product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future earning cash flow company hedge exposure fluctuation currency exchange rate effect asset liability foreign currency enter currency swap contract change spread foreign interest rate company interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future cash flow company enter financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution company significant exposure counterparty management believe risk loss remote total unused credit available company approximate billion include billion credit commitment billion uncommitted line bank worldwide expire september company issue total billion bond shelf registration million debenture million debenture december company file new shelf registration securities exchange commission combination million remain prior shelf registration enable company issue billion unsecured debt security warrant purchase debt new shelf registration effective january johnson johnson continue industrial company triple credit rating total borrowing billion end net cash cash current marketable security net debt billion net cash cash current marketable security net debt billion total debt represent total capital shareholder equity andtotal debt total capital shareholder equity share end compare yearend increase period end december material cash commitment summary borrowing find note information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidated financial statement prepare accordance accounting principle generally accept preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company significant accounting policy describe note company believe understand certain key accounting policy essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal self insurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock option revenue recognition company recognize revenue product sale good ship deliver title risk pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction determine sale period relate sale record provision large medicaid rebate provision base estimate derive current program requirement historical experience company recognize service revenue receive copromotion certain product year present service revenue total revenue include product sale income taxis income taxis record base amount refundable payable current year include result difference gaap account tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect defer tax asset liability record future management believe change estimate result material effect company result operation cash flow financial position company intend continue reinv undistributed international earning expand international operation tax expense record cover repatriation undistribute earning december december cumulative undistribute international earning approximately billion billion respectively legal self insurance contingency company record accrual contingency include legal proceeding product liability case arise normal course business accrual base management judgment probability loss opinion legal counsel applicable actuarially determined estimate additionally company record insurance receivable amount party insurer base probability recovery appropriate reserve receivables record estimate amount collect party insurer longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company fix asset goodwill noncurrent asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan require assumption discount rate expect return plan asset expect salary increase health care cost trend rate note detail rate effect change rate company result operation stock option company elect use accounting principle board opinion accounting stock issue employee apb require compensation cost relate stock option record net incomeas option grant stock option plan exercise price equal market value underlie common stock grant date statement financial accounting standard sfas accounting stockbase compensation transition disclosure amendment fasb statement require pro forma disclosure net income earning share determine fair value method accounting stock option apply measure compensation cost note information stock option new accounting standard june financial accounting standard board fasb issue statement financial accounting standard sfas accounting asset retirement obligation company adopt standard material impact company result operation cash flow financial position june fasb issue sfas accounting cost associate exit disposal activity effective exit disposal activity initiate december company adoption sfas material effect company result operation cash flow financial position november fasb issue fasb interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness interpretation fasb statement rescission fasb interpretation fin clarifie requirement fasb statement accounting contingency relate guarantor accounting disclosure issuance certain type guarantee disclosure requirement fin effective financial statement interim annual period end december provision initial recognition measurement effective prospective basis guarantee issue modify irrespective guarantor yearend fin require issuance guarantee entity recognize liability fair value obligation assume guarantee company adoption fin material effect company result operation cash flow financial position january fasb issue fin consolidation variable interest entity interpretation arb december issue revise fin consolidation variable interest entity interpretation arb address consolidation variable interest entity fin expand criterion consideration determine variable interest entity consolidated business entity require exist unconsolidated variable interest entity include limited special purpose entity spe consolidate primary beneficiary entity effectively disperse risk party involve interpretation immediately applicable variable interest entity create january adoption portion fin material effect company result operation cash flow financial position fin applicable variable interest entity enterprise hold variable interest acquire february company investment arrangement consider variable interest adoption fin anticipate material effect result operation cash flow financial position company april fasb issue sfas amendment statement derivative instrument hedge activity effective contract enter modify june statement amend clarifie financial accounting report derivative instrument include certain derivative instrument embed contract hedging activity company adoption sfas material effect company result operation cash flow financial position fasb issue sfas account certain financial instrument characteristic liabilitie equity effective financial instrument enter modify statement establishe standard issuer classifie measure certain financial instrument characteristic liabilities equity company adoption sfas material effect company result operation cash flow financial position december fasb issue sfas revise employer disclosure pension postretirement benefit amendment fasb statement effective fourth quarter statement revise employer disclosure pension plan postretirement benefit plan disclosure include note december fasb issue fasb staff position fsp fas accounting disclosure requirement relate medicare prescription drug improvement modernization act effective interim annual financial statement fiscal year end december company elect defer adoption fsp fas allow standard company adoption fsp fas expect material effect company result operation cash flow financial position economic market factor johnson johnson aware product environment decade policymaker consumer business express concern rise cost health care response concern johnson johnson long stand policy pricing product responsibly period united states weight average compound annual growth rate johnson johnson price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi inflation rate moderate part world continue effect worldwide economy consequently way company operate face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase company face worldwide health care change result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement december medicare prescription drug improvement modernization act enact introduce prescription drug benefit medicare subsidy sponsor retiree health care benefit plan company elect defer recognition act time authoritative guidance issue measure accumulate postretirement benefit obligation net periodic postretirement benefit cost company financial statement reflect effect act company operate environment increasingly hostile intellectual property right generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend lawsuit result abbreviate new drug application file generic firm introduce generic version product issue result substantial market share revenue loss information discussion litigation filer abbreviate new drug application note common stock market price company common stock list new york stock exchange symbol jnj composite market price range johnson johnson common stock table caption high low high low quarter second quarter quarter fourth quarter yearend close table cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plansexpect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement company assume obligation update forwardlooke statement result new information future event development risk uncertainty include general industry condition competition economic condition interest rate currency exchange rate fluctuation technological advance new product patent attain competitor challenge inherent new product development include obtain regulatory approval challenge patent foreign health care reform governmental law regulation trend health care cost containment increase scrutiny health care industry government agency product efficacy safety concern result product recall regulatory action company report year end december contain exhibit discussion additional factor cause actual result differ expectation company note factor permit private security litigation reform act consolidated balance sheet johnson johnson subsidiaries december december dollar million share share datum note table caption asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note defer taxis income note asset note total asset liabilitie shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer tax liability note employee relate obligation note liabilitie shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share note receivable employee stock ownership plan note accumulate comprehensive income note retain earning common stock hold treasury cost note total shareholder equity total liability shareholder equity table note consolidated financial statement consolidate statement earning johnson johnson subsidiarie dollar million share figure note table caption sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note table note consolidated financial statement consolidate statement equity johnson johnson subsidiaries dollar million note table caption note rec employee compre stock owner hensive retain ship plan total income earning esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock business combination comprehensive income net tax curncy translation adj unrealize gain security gain derivative hedge reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock comprehensive income net tax curncy translation adj unrealize loss security pension liability adj loss derivative hedge reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conver subordinate debenture repurchase common stock business combination comprehensive income net tax curncy translation adj unrealize gain security pension liab adj loss derivative hedge reclassification adj total comprehensive income note receivable esop bal dec table note consolidated financial statement table caption accumul common compre stock treasury hensive issue stock income bal dec net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adj unrealize gain security gain derivative hedge reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adj unrealize loss security pension liability adj loss derivative hedge reclassification adj total comprehensive income note receivable esop bal dec net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adj unrealize gain security pension liability adj loss derivative hedge reclassification adj total comprehensive income note receivable esop bal dec table note consolidated financial statement consolidate statement cash flow johnson johnson subsidiaries dollar million note table caption cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible purchase inprocess research development defer tax provision account receivable reserve change asset liability net effect acquisition business increase account receivable decrease increase inventory increase account payable accrue liability increase current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition business net cash acquire note purchase investment sale investment net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed short term debt retirement short term debt proceed long term debt retirement long term debt proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition business fair value asset acquire fair value liability assume treasury stock issue fair value net cash pay acquisition tablesee note consolidated financial statement note consolidated financial statement summary significant accounting principle principle consolidation financial statement include account johnson johnson subsidiaries intercompany account transaction eliminate new accounting pronouncement june financial accounting standard board fasb issue statement financial accounting standard sfas accounting asset retirement obligation company adopt standard material impact company result operation cash flow financial position june fasb issue sfas accounting cost associate exit disposal activity effective exit disposal activity initiate december company adoption sfas material effect company result operation cash flow financial position november fasb issue fasb interpretation fin guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness interpretation fasb statement rescission fasb interpretation fin clarifie requirement fasb statement accounting contingency relate guarantor accounting disclosure issuance certain type guarantee disclosure requirement fin effective financial statement interim annual period end december provision initial recognition measurement effective prospective basis guarantee issue modify december irrespective guarantor yearend fin require issuance guarantee entity recognize liability fair value obligation assume guarantee company adoption fin material effect company result operation cash flow financial position january fasb issue fin consolidation variable interest entity interpretation arb december issue revise fin consolidation variable interest entity interpretation arb address consolidation variable interest entity fin expand criterion consideration determine variable interest entity consolidated business entity require exist unconsolidated variable interest entity include limited special purpose entity spe consolidate primary beneficiary entity effectively disperse risk party involve interpretation immediately applicable variable interest entity create january adoption portion fin material effect company result operation cash flow financial position fin applicable variable interest entity enterprise hold variable interest acquire february company investment arrangement consider variable interest adoption fin anticipate material effect result operation cash flow financial position company april fasb issue sfas amendment statement derivative instrument hedge activity effective contract enter modify june statement amend clarifie financial accounting report derivative instrument include certain derivative instrument embed contract hedging activity company adoption sfas material effect company result operation cash flow financial position fasb issue sfas account certain financial instrument characteristic liabilitie equity effective financial instrument enter modify statement establishe standard issuer classifie measure certain financial instrument characteristic liabilities equity company adoption sfas material effect company result operation cash flow financial positionin december fasb issue sfas revise employer disclosure pension postretirement benefit amendment fasb statement effective fourth quarter statement revise employer disclosure pension plan postretirement benefit plan disclosure include note december fasb issue fasb staff position fsp fas accounting disclosure requirement relate medicare prescription drug improvement modernization act effective interim annual financial statement fiscal year end december company elect defer adoption fsp fas allow standard company adoption fsp fas expect material effect company result operation cash flow financial position cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value longterm debt security company ability intent hold maturity carry amortize cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment nonmarketable equity security impairment adjust investment fair value decline market value deem temporary property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset table building building equipment year land leasehold improvement year machinery equipment year table company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow necessary charge impairment longlive asset record present value future cash flow carry value asset revenue recognition company recognize revenue product sale good ship deliver depend title risk pass customer provision certain rebate sale incentive trade promotion product return discount customer provide reduction determine sale period relate sale record company recognize service revenue receive copromotion certain product sale incentive trade promotional allowance company adopt emerge issue task force eitf issue account consideration give vendor customer reseller vendor product effective december sale reduce million cost product sell increase million shipping handling shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost market determine firstin firstout method intangible asset accordance sfas amortization record goodwill andor intangible asset deem indefinite life acquisition complete june effective begin fiscal year accordance sfas company discontinue amortization relate exist goodwill indefinite live intangible asset sfas effective effect reduce amortization expense million tax intangible asset finite useful life continue amortize useful life sfas require goodwill nonamortizable intangible asset assess annually impairment company complete annual impairment test fiscal fourth quarter impairment determine future impairment test perform fiscal fourth quarter annually financial instrument company follow provision sfas accounting derivative instrument hedge activity amend sfas account certain derivative instrument certain hedging activity amendment fasb statement collectively refer sfas sfas require derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction depend type hedge transaction company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product party purchase raw material denominate foreign currency company use currency swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use forward exchange contract offset exposure certain foreign currency asset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability designation cash flow hedge date enter derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction fair value forward exchange contract represent present value change forward exchange rate times notional derivative fair value currency swap contract determine discount present future cash flow currency exchange interest rate prevail market period currency exchange express result dollar current spot foreign currency exchange rate ongoing basis company assess derivative continue highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financialperformance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically additional information available receivables insurance recovery relate product liability relate claim record undiscounted basis probable recovery realize research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion income taxis company intend continue reinv undistributed international earning expand international operation tax expense record cover repatriation undistribute earning december december cumulative undistribute international earning approximately billion billion respectively defer income taxis recognize tax consequence temporary difference apply enact statutory tax rate applicable future year difference financial reporting tax basis exist asset liability net earning share basic earning share compute divide net income available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security contract issue common stock exercise convert common stock stock option december company stockbase employee compensation plan describe note company account plan recognition measurement principle accounting principle board opinion accounting stock issue employee apb relate interpretation compensation cost record net income stock option option grant plan exercise price equal market value underlie common stock date grant require sfas accounting stockbase compensation transition disclosure amendment fasb statement follow table show estimate effect net income earning share company apply fair value recognition provision sfas accounting stockbase compensation stockbase employee compensation table caption dollar million share datum net income report compensation expense pro forma earning share basic report pro forma diluted report pro forma table determine fair value base method awards net tax use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report actual result differ estimate annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year case fiscal year consist week reclassification certain prior year amount reclassify conform current year presentation stock split april board director declare stock split shareholder record close business issue additional share johnson johnson common stock june share hold record date share share datum period present financial statement adjust reflect stock split inventory end inventory comprise table caption dollar millions raw material supply good process finish good table property plant equipment end property plant equipment cost accumulate depreciation table caption dollar millions land land improvement building build equipment machinery equipment construction progress accumulate depreciation table company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billionrespectively retirement disposal fix asset cost relate accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed adjust earning rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december table caption dollar million total table commitment capital lease significant employee relate obligation end employee relate obligation table caption dollar millions pension benefit postretirement benefit postemployment benefit defer compensation current benefit payable employee relate obligation table prepay employee relate obligation million million respectively include asset consolidate balance sheet borrowing component longterm debt follow table caption eff eff dollars millions rate rate zero coupon convertible subordinated debenture debenture debenture debenture note debenture eurodollar note note convertible subordinated note note zero coupon convertible subordinated debenture industrial revenue bond current portion table weight average effective rate represent dollar note issue japanese subsidiary convert fix rate yen note currency swap company access substantial source fund numerous bank worldwide total unused credit available company approximate billion include billion credit commitment billion uncommitted line bank worldwide expire interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material yearend company billion remain shelf registration company issue total billion bond shelf million debenture million debenture december company file new shelf registration securities exchange commission combination million remain prior shelf registration issue billion debt security warrant purchase debt security new shelf registration effective january long term debt include convertible subordinated debenture issue alza corporation scios inc prior company wholly own subsidiary johnson johnson august scios inc issue private offering million convertible subordinated note interest payable semiannually february august note convertible option holder time prior redemption repurchase maturity conversion price follow acquisition johnson johnson april principal note convertible right receive cash interest semiannual interest remain payable conversion repurchase maturity december book value note approximate fair value july alza complete private offering zero coupon convertible subordinated debenture issue price principal maturity december outstanding debenture total principal maturity billion yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture holder entitle convert debenture approximately million share johnson johnson stock price share approximately share issue december voluntary conversion note holder option holder debenture repurchase company july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver johnson johnson common stock cash combination stock cash event repurchase debenture company option redeem debenture july issue price plus accrete original issue discount december december fair value base quote market value debenture million million respectively alza issue zero coupon convertible subordinated debenture price principal maturity december outstanding debenture total principal maturity million yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture note holder entitle convert theirdebenture approximately million share johnson johnson stock price share approximately million share johnson johnson stock issue december voluntary conversion debenture holder option holder debenture purchase company july july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver common stock cash event conversion purchase debenture company option redeem debenture cash july redemption price equal issue price plus accrete original issue discount december december fair value base quote market value debenture million million respectively shortterm borrowing current portion longterm debt amount billion end borrowing comprise million commercial paper million eurodollar note mature million local borrowing principally international subsidiary aggregate maturity longterm obligation commence table caption dollar millions table intangible asset end gross net amount intangible asset table caption dollar millions goodwill gross accumulate amortization goodwill net trademark nonamortizable gross accumulate amortization trademark nonamortizable net patent trademark gross accumulate amortization patent trademark net intangible gross accumulate amortization intangible net total intangible asset gross accumulate amortization total intangible asset net table goodwill december allocate segment business follow table caption med dev dollar million consumer pharm diag total goodwill net accumulate amortization december acquisition translation goodwill december table weight average amortization period patent trademark otherintangible asset year year respectively amortization expense amortizable intangible asset fiscal year end december million tax estimate amortization expense succeed year approximate million tax year income taxis provision taxis income consist table caption dollar millions currently payable tax international taxis defer taxis international taxis table comparison income tax expense federal statutory rate company effective tax rate follow table caption dollar millions international earning taxis income statutory taxis tax rate statutory puerto rico ireland operation research tax credit state local international subsidiary exclude ireland iprd effective tax rate table company subsidiary operate puerto rico tax incentive grant addition company subsidiary manufacture ireland incentive tax rate temporary difference carry forwards follow table caption defer tax defer tax dollar million asset liability asset liability employee relate obligation depreciation nondeductible intangible international capitalize tax reserve liabilitie income report tax purpose miscellaneous international capitalize intangible miscellaneous total deferred income taxis table difference net defer tax income balance sheet net defer tax include taxis income balance sheet international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy reflect operating result analysis change foreign currency translation adjustment include note net currency transaction translation gain loss include expense tax loss million million million respectively common stock stock option plan stock compensation agreement december company stockbase compensation plan stock option plan company grant option employee issue share company common stock plus number share available previous year issue share issue plan expired terminate exercised share outstanding contract company stock option plan nonemployee director plan mitek cordis biosense gynecare centocor innovasive device alza inverness scio stock option plan option grant plan stock option plan scio stock option plan preacquisition stock option expire year date grant vest service period range year option grant current market price date grant share available stock option plan future grant base issue share year million share grant year year addition available share describe share available future grant plan million end summary status company stock option plan december december december change year end date present table caption weight option average share thousand outstanding exercise price balance december option grant option exercise option canceledforfeite balance december option grant option exercise option canceledforfeite balance december option grant option exercise option canceledforfeite balance december table include option issue replace inverness option outstanding orgrante prior acquisition include option issue replace scio option outstanding grant prior acquisition year end december change timing grant stock compensation option employee december february change enact result finalize order align compensation performance timing grant follow prospectively average fair value option grant fair value estimate blackschole option pricing model base weighted average assumption table caption riskfree rate volatility expect life yrs yrs yrs dividend yield table follow table summarize stock option outstanding exercisable december share thousand table caption outstanding exercisable average average exercise average exercise exercise price range option lifea price option price table average contractual life remain year stock option exercisable december december option average price option average exercise price respectively segment business geographic area accumulate comprehensive income component comprehensive incomeloss consist follow dollar million table caption total unrld gain accum gain pen loss cur loss liab deriv comp trans sec adj hedg incloss dec net change dec change net change dueto hedging transaction net reclasse net earning net change dec change net change hedging transaction net reclasse net earning net change dec table total comprehensive income include reclassification adjustment loss million realize sale equity security associate tax benefit million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million tax effect unrealize gainslosses equity security expense million benefit million expense million tax effect gainslosse derivative hedge benefit million million respectively expense million note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment international subsidiary pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care retire employee dependent international employee cover governmentsponsored program cost company significant retirement plan benefit primarily base employee compensation year retirement number year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree health care benefit advance right modify plan future december sfas revise employer disclosure pension postretirement benefit issue amend disclosure requirement pension postretirement benefit revise statement address disclosure address liability measurement expense recognition company use date consolidate financial statement december december respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component table caption retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial lossesgain curtailment settlement special termination benefit net periodic benefit cost table net periodic cost attributable retirement plan million million million company offer voluntary retirement program enhance benefit call retirement enhancement program rep eligible regular fulltime employee attain age year pension credit service june program enhancement include elimination early retirement reduction pension benefit purpose normally year prior age special termination benefit week pay year credit service program result increase pension expense million reflect value retirement enhancement weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year table caption retirement plan benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level table table caption benefit plan benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level table expect longterm rate return plan asset assumption determine building block approach consider historical average realreturn asset class certain country historical return meaningful consideration give local market expectation longterm return follow table display assume health care trend rate individual table caption worldwide benefit plan health care trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate table onepercentagepoint change assume health care cost trend rate follow effect table caption onepercentage onepercentage dollar million point increase point decrease worldwide benefit plan total interest service cost postretirement benefit obligation table follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan table caption retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial loss divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contrib divestitures benefit pay plan asset effect exchange rate plan asset fair value end year table strategic asset allocation determine country base nature liability consider demographic composition plan participant average age year service active versus retiree status company plan consider nonmature plan longterm strategic asset allocation consistent type plan emphasis place diversify equity broad basis combine currency match fix income asset derivative primarily hedge currency exposurethe company expect fund retirement plan order meet minimum statutory funding requirement international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain country united states fund pension plan common practice funding provide economic benefit consequently company pension plan fund company expect contribute million benefit plan meet current year medical claim obligation follow table display project future contribution company unfunded retirement plan table caption dollar millions retirement plan unfunded retirement plan table company retirement plan asset allocation end target allocation follow table caption percent target plan asset allocation dollar millions retirement plan equity security debt security total plan asset international retirement plan equity security debt security real estate total plan asset table company benefit plan unfunded life insurance contract asset million million december december respectively fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset december amount recognize company balance sheet consist follow table caption retirement plan benefit plan dollar million plan asset fair value project benefit obligation fund status unrecognize actuarial loss unrecognize prior service cost unrecognized nettransition asset total recognize consolidated balance sheet table table caption retirement plan benefit plan dollar million book reserve prepay benefit intangible asset accumulate comprehensive income total recognize consolidated balance sheet table accumulate benefit obligation international define benefit retirement plan billion billion december december respectively minimum pension liability adjustment require actuarial present value accumulate benefit obligation abo exceed fair value plan asset accrue pension liability minimum pension liability intangible asset accumulate comprehensive income million million respectively relate primarily plan outside increase minimum liability include comprehensive income million million respectively plan accumulate benefit obligation excess plan asset consist follow table caption retirement plan dollar millions accumulate benefit obligation project benefit obligation plan asset fair value table december medicare prescription drug improvement modernization act enact introduce prescription drug benefit medicare subsidy sponsor retiree health care benefit plan company elect defer recognition act time authoritative guidance issue measure accumulate postretirement benefit obligation net periodic postretirement benefit cost company financial statement reflect effect act marketable security table caption december real real est net ize ize fair cost gain loss value money market fund commercial paper time deposit government security obligation bank note corporate debt security total current marketable security government security bank note corporate debt security investment hold trust total noncurrent marketable security table table caption december real real est net ize ize fair cost gain loss value money market fund commercial paper time deposit government security obligation bank note corporate debt security total current marketable security government security bank note corporate debt security investment hold trust total noncurrent marketable security table current marketable security include billion billion classified cash equivalent balance sheet december december respectively financial instrument company follow provision sfas require derivative instrument record balance sheet fair value december balance defer net loss derivative include accumulate comprehensive income million aftertax additional information note company expect substantially reclassify earning month result transaction expect occur period ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative transaction party cause accumulate comprehensive income affect net earning maximum length time company hedge month year end december net impact hedge ineffectiveness company financial statement insignificant year end december company record net gain million tax income expense net category consolidate statement earning represent impact discontinuance cash flow hedge probable originally forecast transaction occur end originally specify time period refer note disclosure movement accumulate comprehensive income concentration credit risk company invest excess cash deposit major bank world high quality money market instrument refer note additional information company policy make investment commercial institution equivalent credit rating investment generally mature month company incur relate loss saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible salary plan onethird company match pay company stock employee stock ownership plan esop employee chooses redirect investment establish esop company loan million esop trust purchase share company stock open market exchange company receive note balance record reduction shareholder equity total company contribution plan million million million merger acquisition divestiture certain business acquire billion cash million liability assume acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include link spine group inc privately own corporation exclusive worldwide right charite artificial disc scios inc biopharmaceutical company market product cardiovascular disease research project focus autoimmune disease dimensional pharmaceuticals inc company technology platform focus discovery development therapeutic small molecules orapharma inc specialty pharmaceutical company focus development commercialization unique oral therapeutic certain asset orquest inc privately hold biotechnology company focus develop biologicallybase implant orthopaedic spine surgery excess purchase price estimate fair value tangible asset acquire amount billion allocate identifiable intangible goodwill approximately million identify value inprocess research development iprd primarily associate acquisition link spine group inc scios inc iprd charge relate link spine acquisition million associate charite artificial disc charite artificial disc market country outside premarket approval application file food drug administration february value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate preliminary basis purchase price link spine acquisition allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date excess purchase price fair value asset liability acquire approximately million allocate goodwill company expect substantially allocate goodwill deductible tax purpose iprd charge relate scio million largely associate kinase inhibitor program value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor discount rate preliminary basis purchase price scios inc acquisition allocate tangible andidentifiable intangible asset acquire liability assume base estimate fair value acquisition date identifiable intangible asset include patent trademark value approximately billion excess purchase price fair value asset liability acquire approximately million allocate goodwill company expect substantially allocate goodwill deductible tax purpose remain iprd associate orquest inc dimensional pharmaceutical inc charge million million respectively case value iprd calculate assistance party appraiser certain business acquire million cash liability assume million acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include tibotecvirco privatelyheld biopharmaceutical company focus develop antiviral treatment micro typing systems inc manufacturer reagent supplier distribute instrument know idmicro type system obtech medical privatelyheld company market adjustable gastric band treatment morbid obesity excess purchase price estimate fair value tangible asset acquire entity amount million allocate identifiable intangible goodwill approximately million identify value iprd associate tibotecvirco obtech medical acquisitions iprd charge related tibotecvirco million associate early stage hiv compound value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor range discount rate iprd charge relate obtech medical million associate development current swedish adjustable gastric band sagb use united states development generation technology platform value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor discount rate supplemental pro forma information sfas business combination sfas goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position june johnson johnson alza corporation alza complete merger company transaction account poolingofinterest alza approximately million share outstanding million fully dilute basis exchange approximately million share johnson johnson common stock dilute basis adjust stock option convertible debt total number johnson johnson share issue approximately million holder alza common stock receive share johnson johnson common stock value share alza researchbased pharmaceutical company lead drug delivery technology company apply delivery technology develop pharmaceutical product enhance therapeutic value johnson johnson affiliate portfolio world lead pharmaceutical company certain business acquire billion billion cash liability assume million share company common stock issue treasury value billion acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include inverness medical technology inc supplier lifescan electrochemical product blood glucose monitoring follow spinoff nondiabetes business heartport inc company thatdevelop manufacture product invasive open chest minimally invasive heart operation include stop heart beat heart procedure terame corporation earlystage medical device company develop endovascular stentgraft system minimally invasive treatment abdominal aortic aneurysm peripheral occlusive disease babycenter llc internet content commerce company devote support community expectant new mother viactiv product line chewable calcium supplement mead johnson nutritional division bristolmyer squibb inverness medical technology acquire enhance control primary supplier lifescan blood glucose monitoring product allow achievement operational synergies acquisition provide key technology development future product approximately million identify value iprd associate inverness medical technology terame corporation acquisition iprd charge primarily relate inverness project minimally invasive testing continuous monitoring insulin delivery value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor range discount rate divestiture material effect company result operation cash flow financial position legal proceeding product liability litigation company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover reserve establish selfinsurance program commercially available excess liability insurance group case company concern janssen pharmaceutica product propulsid withdraw general sale restrict limited use wake publicity event numerous lawsuit file janssen wholly own subsidiary company company propulsid state federal court country approximately case currently pende include claim approximately plaintiff active case individual allege die use propulsid action seek substantial compensatory punitive damage accuse janssen company inadequately testing warning drug effect promote offlabel use promotion addition janssen company enter agreement plaintiff counsel halting run statute limitation respect potential claim tolling agreement significant number individual attorney evaluate sue janssen company behalf september plaintiff rankin case comprise claim propulsid plaintiff go trial state court claiborne county mississippi jury return compensatory damage verdict plaintiff million total million trial judge dismiss claim punitive damage march trial judge reduce verdict total million deny motion janssen company new trial janssen company believe verdict reduce insupportable appeal view janssen company proof trial demonstrate plaintiff injure propulsid basis liability exist april state court judge new jersey deny plaintiff motion certify national class propulsid user purpose medical monitoring refund cost purchase propulsid effort appeal ruling deny june federal judge preside propulsid multidistrict litigation new orleans louisiana similarly deny plaintiff motion certify national class propulsid user plaintiff multidistrict litigation say preserve right appeal ruling complaint file janssen company include class action allegation basis future attempt class certify february janssen announce reach agreement principle plaintiff steer committee psc propulsid federal multidistrict litigation mdl resolve federal lawsuit relate propulsid approximately individual include federal mdlof approximately allege die use drug agreement effective percent death claim percent remainder agree term settlement addition individual file lawsuit claim subject tolling agreement suspend run statute limitation claim agree participate settlement effective agree participate settlement submit medical record independent panel physician determine claim injury cause propulsid meet standard compensation standard meet courtappointe special master determine compensatory damage janssen pay compensation minimum million maximum million depend number plaintiff enroll program janssen establish administrative fund exceed million pay legal fee psc million subject court approval respect propulsid action janssen company dispute claim lawsuit vigorously defend judgment settlement appropriate janssen company believe adequate selfinsurance reserve commercially available excess insurance respect case communication company excess insurance carrier raise certain defense liability policy date decline reimburse janssen company propulsidrelate cost despite demand payment opinion company defense pro forma lack substance carrier honor obligation policy voluntarily litigation company recently commence arbitration allianz underwriter insurance company issue layer applicable excess insurance coverage obtain reimbursement propulsidrelate cost company ethicon inc subsidiary year number claim lawsuit file relate vicryl sutures action allege sterility vicryl suture compromise inadequacy ethicon system control cause patient expose suture incur infection occur ethicon occasion recall batch vicryl suture light question raise sterility believe contamination suture product fact occur november trial judge west virginia certify class treatment west virginia resident vicryl suture implant class surgery december certification subject later challenge follow conclusion discovery trial date set matter ethicon intend continue vigorously contest liability affirmative stent patent litigation patent infringement action try delaware federal court late cordis corporation subsidiary johnson johnson obtain verdict infringement patent validity damage awards boston scientific corporation medtronic ave inc base number cordis vascular stent patent december jury damage action boston scientific return verdict million december jury medtronic ave action return verdict million sum represent lose profit reasonable royalty damage compensate cordis infringement include pre post judgment interest february hearing hold claim boston scientific medtronic ave patent issue unenforceable owe allege inequitable conduct patent office march district judge issue post trial ruling confirm validity enforceability main cordis stent patent claim find certain cordis patent unenforceable district judge grant boston scientific new trial liability damage vacate verdict medtronic ave legal ground august court appeal federal circuit find trial judge err vacate verdict medtronic ave remand case trial judge proceeding medtronic ave motion reconsideration panel reconsideration court deny october request stay return mandate trial court pende filing request writ certiorari united states supreme court deny october medtronic ave file petition writ certiorari united states supreme court january cordis file motion trial court october reinstate verdict medtronic ave boston scientific award interest enter injunction stent product issue case gfx andmicrostent stent medtronic ave nir stent boston scientific colorable variation thereof medtronic ave boston scientific resist reinstatement verdict likely attempt appeal court appeal federal circuit judgment enter january cordis file additional patent infringement action boston scientific delaware federal court accuse express taxus stent infringe cordis patent involve early action boston scientific medtronic ave february cordis move action preliminary injunction seek bar introduction taxus stent base patent november district judge deny request preliminary injunction cordis file appeal court appeal federal circuit decision federal circuit expect quarter cordis pende delaware federal court action medtronic ave accuse medtronic ave infringement stent product introduce medtronic ave subsequent gfx microstent product subject early action reference early june arbitration panel chicago preliminary ruling find favor cordis arbitration acsguidant involve infringement acsguidant cordis stent patent august panel confirm ruling reject challenge acsguidant term early agreement cordis acsguidant arbitration panel rule obligate acsguidant payment million cordi fiscal fourth quarter result resolve matter fiscal fourth quarter million record income expense approximately million tax relate past period balance award million approximately million tax recognize income future period estimate remain life intellectual property additional royalty acsguidant continue use technology injunction involve patent litigation johnson johnson operate company product johnson johnson operate company subject patent lawsuit potentially affect ability operate company sell product require payment past damage future royalty follow patent lawsuit concern important product johnson johnson operating company boston scientific medinol ltd cordis corporation action file delaware federal court december charge infringement velocity cordis stent product certain patent own medinol license boston scientific case try jury september result verdict cordis noninfringement invalidity respect minor stent product jury find infringement award damage million medinol file appeal result affirm court appeal federal circuit january medtronic ave cordis corporation action file april federal district court texas transfer federal district court delaware assert certain patent own medtronic ave cordis velocity stent stent structure cypher drugelute product federal district court delaware recently reverse prior decision stay lawsuit pende outcome arbitration party issue cordis license patent assert medtronic ave boston scientific corporation bsc cordis corporation action file delaware federal court march assert cypher drugelute stent infringe patent assign boston scientific boston scientific seek damage permanent injunction boston scientific corporation bsc cordis corporation action file delaware federal court december assert cordis cypher drug eluting stent infringe patent assign bsc neorx pertain pharmaceutical compound use stent bsc seeking damage permanent injunction medinol ltd cordis europe netherlands medinol ltd cordis holding belgium bvba janssen pharmaceutica belgium july appeal court hague overturn low court grant medinol israeli stent manufacturer preliminary injunction base patent infringement prohibit cordis make sell velocity cypher stent netherlands injunction effective august belgium medinol file patent infringement suit base patent assert netherlands move preliminary injunction seek prevent defendant make sell velocity cypher stent motion deny trial court november medinol appeal cordis currently use janssen pharmaceutica facility belgium coat cypher stent sirolimus principally exus market rockey cordis corporation action cordis heirs drrockey concern patent license cordis shortly cordis acquire johnson johnson plaintiffs assert rockey patent expire february cover stent product market cordi seek royalty sale trial action pende federal court miami florida schedule march february ascguidant cordis corporation enter strategic alliance copromotion drugeluting stent result agreement pende litigation company settle respect matter johnson johnson operate company involve vigorously defend claim infringement dispute appropriate validity enforceability patent claim assert litigation filer abbreviate new drug application anda follow lawsuit generic firm file abbreviate new drug application anda seek market generic form product sell subsidiary company prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability patent event subsidiary company involve successful action firm involve introduce generic version product issue result substantial market share revenue loss product company subsidiary orthomcneil pharmaceutical inc daiichi inc mylan laboratory orthomcneil pharmaceutical inc daiichi inc teva pharmaceutical matter file february federal court west virginia second june federal court new jersey concern effort mylan teva invalidate establish noninfringement unenforceability patent cover levaquin levofloxacin tablets patent own daiichi exclusively license orthomcneil phase trial mylan case conclude december second phase conclude trial date set teva matter orthomcneil pharmaceutical inc daiichi bedford laboratory matter file federal district court new jersey april involve effort bedford invalidate assert noninfringement unenforceability daiichi patent levaquin involve proceeding case bedford challenge patent application product assert equivalent levaquin injection premix injection vial tablet orthomcneil pharmaceutical inc daiichi american pharmaceutical partner sicor pharmaceutical december orthomcneil pharmaceutical inc daiichi file suit federal district court new jersey american pharmaceutical partner sicor pharmaceutical respect andas file entity involve daiichi patent levaquin injection premix single use vial janssen pharmaceutica inc alza corporation mylan laboratory action file federal district court vermont january concerns mylan effort invalidate assert noninfringement unenforceability alza patent cover duragesic fentanyl transdermal system product trial conclude september posttrial briefing complete december mylan state publicly intend launch generic duragesic july lose case district court assert janssen alza forfeited benefit fda grant pediatric exclusivity file lawsuit late janssen alza vigorously dispute contention janssen pharmaceutica eon labs manufacturing action file federal court eastern district new york april concern eon effort invalidate establish noninfringement janssen patent cover sporanox itraconozole trial date schedule orthomcneil pharmaceutical inc kali laboratories inc lawsuit file federal court new jersey november concerns attempt kali invalidate establish noninfringement orthomcneil patent cover ultracet tramadolacetaminophen tablet trial date set case alza corporation mylan laboratory action file federal district court west virginia concern mylan effort invalidate assert noninfringement alza patent cover orthomcneil product ditropan oxybutynin chloride trial schedule february case alza corporation impax laboratory action file federal court california september concerns impax effort invalidate assert noninfringement alza patent cover ditropan involve mylan case trial date set matter orthomcneil pharmaceutical inc barr laboratories inc action file federal district court new jersey october concern effort barr laboratory assert noninfringement invalidity unenforceability orthomcneil patent ortho tricyclen lonorgestimateethinyl estradiol oral contraceptive product janssen pharmaceutica mylan pharmaceuticals inc action file federal district court new jersey december concern mylan effort invalidate janssen patent cover risperdal risperidone tablet janssen pharmaceutica reddy laboratory inc action file federal district court new jersey concern reddy effort invalidate janssen patent cover risperdal tablet immediately precede mylan case eisai inc reddy laboratory inc action file janssen copromotion partner eisai inc federal court new york concern reddy effort invalidate assert noninfringement eisai patent cover aciphex rabeprazole sodium tablet trial date set eisai inc teva pharmaceuticals usa action file janssen copromotion partner eisai inc concern teva effort invalidate assert noninfringement eisai patent involve immediately precede reddy case trial date set matter eisai inc mylan pharmaceuticals inc january janssen copromotion partner eisai inc file action federal district court new york mylan pharmaceuticals inc mylan effort invalidate assert noninfringement eisai patent cover aciphex tablet reddy teva case trial date set janssen pharmaceutica inc party eisai action respect matter johnson johnson operate company involve vigorously defend validity enforceability assert infringement licensor patent average wholesale price awp litigation johnson johnson pharmaceutical operating company numerous pharmaceutical company defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation mdl federal court boston massachusetts plaintiffs case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp ethicon endosurgery inc johnson johnson operate company market endoscopic surgical instrument company name defendant north carolina state court class action lawsuit allege awp inflation improper marketing activity tap pharmaceutical ethicon endosurgery inc defendant base claim sale representative allege involve arbitrage tap drug allegation sale representative persuade certain physician states drug price low purchase tap excess quantity drug resell state price high ethicon endosurgery inc company deny liability claim case vigorously defend trial judge recently certify national class purchaser tap product issue trial likely new york state attorney general office federal trade commission issue subpoenas january february seek document relate marketing suture endoscopic instrument company ethicon inc ethicon endosurgery inc subsidiary connecticut attorney general office issue subpoena document subpoena focus bundle suture endoscopic instrument contract offer group purchasing organization individual hospital discount predicate hospital achieving specify market share target category product operating company involve respond subpoenas june company receive request record information house representatives committee energy commerce connection investigation pharmaceutical reimbursement rebate medicaid committee request focus drug remicade infliximab market company centocor inc subsidiary july centocor receive request voluntarily provide document information criminal division attorney office district new jersey connection investigation centocor marketing practice company centocor respond request document information august securities exchange commission sec advise company informal investigation foreign corrupt practice act allegation payment polish governmental official pharmaceuticalcompanie november sec advise company investigation formal issue subpoena information previously request informal fashion plus background document company operating unit poland respond request december company orthomcneil pharmaceutical unit receive subpoena united states attorney office boston massachusetts seek document relate marketing include alleged offlabel market ing drug topamax topiramate approve antiepilepsy therapy orthomcneil cooperating respond subpoena january company janssen unit receive subpoena office inspector general united states office personnel management seek document concern payment physician connection sale marketing clinical trial risperdal janssen cooperate respond subpoena company record million damage million legal fee cost connection arbitration proceeding file involve company ortho biotech subsidiary amgen ortho biotech licensor nondialysis right procrit epoetin alfa amgen seek terminate ortho biotech license right collect substantial damage proceed base allege deliberate procrit sale ortho biotech early amgen reserve dialysis market october arbitrator issue decision reject amgen request terminate license find material breach license arbitrator find conduct ortho biotech early subsequently halt ortho biotech amount nonmaterial breach license award amgen million damage company accrue quarter january arbitrator rule amgen prevail party arbitration entitling award reasonable attorney fee cost company accrue million fourth quarter connection claim remand federal circuit court appeal january partial retrial commence october conclude november boston massachusetts action amgen transkaryotic therapy inc tkt aventis pharmaceutical inc matter patent infringement action bring amgen tkt developer geneactivate epo product aventis hold marketing right tkt product assert tkt product infringe amgen patent claim tkt aventis dispute infringement seek invalidate amgen patent assert district court issue preliminary ruling uphold district court initial finding opinion district court expect second quarter proceeding appeal follow amgen patent issue case exclusively license ortho biotech inc johnson johnson operating company nondialysis indication ortho biotech inc party action company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty opinion management base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company consolidated balance sheet expect material adverse effect company consolidated financial position resolution report period matter significant impact company result operation cash flow period earning share follow reconciliation basic net earning share dilute net earning share year end december december december table caption share millions basic earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted earning share table dilute earning share calculation include dilution effect convertible debt decrease interest expense million million million tax year respectively dilute earning share exclude million share underlie stock option million share underlie stock option year exercise price option great average market value result antidilutive effect dilute earning share capital treasury stock change treasury stock table caption treasury stock dollar million number share thousand share balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december table share common stock issue share end select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize dollar million share datum table caption second fourth qtr qtr qtr qtr segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share table dollar million share datatable caption second fourth qtr qtr qtr qtr segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share table quarter include tax charge million inprocess research development iprd cost second quarter include tax charge million iprd cost fourth quarter include tax income million arbitration ruling stent patent cost retirement enhancement program million second quarter include tax charge million iprd cost quarter include tax charge million amgen arbitration settlement fourth quarter include tax charge million amgen arbitration settlement report independent auditor shareholder board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning consolidate statement equity consolidate statement cash flow present fairly material respect financial position johnson johnson subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion discuss note financial statement company adopt statement financial accounting standard goodwill intangible asset effective december pricewaterhousecooper llp pricewaterhousecooper llp new york new york january fifth thirteenth paragraph note date february february respectively segment business johnson johnson subsidiaries table caption sale customer dollar million consumer united states international total pharmaceutical united states international total med devices diag united states international total worldwide total table table caption operating profit dollar million consumer pharmaceutical medical device diagnostic segment total expense allocate segment worldwide total table table caption identifiable asset dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total table table caption addition property plant equipment dollar millions consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total table table caption depreciation amortization dollar millions consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total table table caption sale customer dollar million united states europe western hemisphere exclude asiapacific africa worldwide total table table caption longlive asset dollar million united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total table management discussion analysis description segment company business export sale intersegment sale significant sale distributor account sale concentrated pharmaceutical segment sale procriteprex account total company revenue respectively amount allocate segment include interest incomeexpense minority interest general corporate income expense general corporate include cash marketable security include million inprocess research development iprd pharmaceutical segment million iprd million arbitration ruling stent patent medical device diagnostic segment include million iprd million million cost relate arbitration settlement procrit pharmaceutical segment million iprd medical device diagnostic segment include million alza merger cost pharmaceutical segment million iprd summary operation statistical datum johnson johnson subsidiariesdollar million share figure table caption sale customer domestic sale customer international total sale cost product sell sell marketing admin expense research expense purchase inprocess research develop interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maint repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand table adjust reflect twoforone stock split period adjust include effect alza merger net interest income include cost material service category include taxis income payroll property business taxis dollar million share figure table caption sale customer domestic sale customer international total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plantand equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand table adjust reflect twoforone stock split period adjust include effect alza merger net interest income include cost material service category include taxis income payroll property business taxis text document document typeex sequence filenameyexvtxt descriptionsubsidiarie text exhibit subsidiary johnson johnson new jersey corporation domestic international subsidiary show certain subsidiary international subsidiary name significant aggregate johnson johnson parent table caption jurisdiction subsidiary organization subsidiaries dimensional pharmaceuticals inc delaware investments inc delaware alza corporation delaware alza land management inc delaware biosense webster inc california centocor inc pennsylvania codman shurtleff inc new jerseycordis corporation florida cordis international corporation delaware cordis llc delaware crescendo pharmaceuticals corporation delaware depuy disc inc delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc new mexico ethicon endosurgery services texas ethicon inc new jersey ethicon llc delaware gynopharma inc delaware heartport inc delaware independence technology llc new jersey iso merger corp delaware janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products new jersey jjhc inc delaware johnson johnson baby products inc delaware johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey table table caption jurisdiction subsidiary organization johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceutical new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson professional inc delaware johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical product corporation delaware lifescan inc california lifescan llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products new jersey orthoclinical diagnostics inc new york orthomcneil finance florida orthomcneil pharmaceutical inc delaware rutan realty llc new jersey scios inc delaware splenda inc delaware terame corporation delaware therakos inc florida tylenol company new jersey winthorpe valentine inc delaware international subsidiary abello farmacia spain alza ireland limited ireland apsis sarl francecentra medicamenta otc srl italy cilag switzerland cilag international switzerland cilag mexico mexico cilag holding switzerland cordis mexico mexico cordis europa netherlands cordis italia spa italy cordis medizinische apparate gmbh germany table table caption jurisdiction subsidiary organization cordis france cordis sarl switzerland depuy ace sarl switzerland depuy australia pty ltd australia depuy france france depuy international ltd united kingdom depuy intl holdings ltd united kingdom depuy ireland limited ireland depuy italia spa italy depuy japan japan depuy orthopadie gmbh germany depuy orthopedie france depuy spine sarl switzerland depuy holdings limited united kingdom ethicon endosurgery europe gmbh germany ethicon gmbh germany ethicon ireland limited ireland ethicon limited scotland ethicon sas france ethicon spa italy ethnor proprietary limited south africa greiter switzerland greiter international switzerland inverness medical limited scotland janssen animal health bvba belgium janssencilag denmark janssencilag norway janssencilag sweden janssencilag switzerland janssencilag netherlands janssencilag venezuela janssencilag egypt ltd egypt janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd united kingdom janssencilag belgium janssencilag finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag pty limited australia janssencilag spain janssencilag mexico janssencilag sas france janssencilag spa italy janssen internationaal cvba belgium janssen korea ltd korea table table caption jurisdiction subsidiary organization janssenortho inc canada janssen pharmaceutica limited thailand janssen pharmaceutica belgiumjanssen pharmaceutica pty limited south africa janssen pharmaceutical japan janssen pharmaceutical limited ireland healthcare ltd israel jhc nederland netherlands johnson johnson sweden johnson johnson switzerland johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson comercio distribuicao ltda brazil johnson johnson consumer france sas france johnson johnson consumer nvsa belgium johnson johnson argentina sace argentina johnson johnson colombia colombia johnson johnson venezuela venezuela johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited england johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas greece johnson johnson holding sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson international financial services company ireland johnson johnson international france johnson johnson investments limited england johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson kft hungary johnson johnson japan johnson johnson korea ltd korea johnson johnson lda portugal johnson johnson limited india johnson johnson ltd england johnson johnson management limited england johnson johnson medical netherlands johnson johnson medical china ltd china johnson johnson medical korea limited korea johnson johnson medical limited scotland johnson johnson medical mexico mexico table table caption jurisdiction subsidiary organization johnson johnson medical nvsa belgium johnson johnson medical pty limited south africa johnson johnson medical pty limited australia johnson johnson medical argentina johnson johnson morocco morocco johnson johnson new zealand limited new zealand johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland poland johnson johnson private limited zimbabwe johnson johnson products inc canada johnson johnson produtos profissionais ltda brazil johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty limited australia johnson johnson spain johnson johnson mexico johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson spolsro czech republic johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailandjohnson johnson vision care ireland limited ireland laboratoire martin johnson johnson msd sas france laboratoire polive snc france lifescan canada ltd canada mcneil consumer nutritionals ltd england medos switzerland neutrogena provence sarl france obtech medical switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostic united kingdom orthoclinical diagnostic gmbh germany orthoclinical diagnostic japan orthoclinical diagnostic belgium orthoclinical diagnostic france orthoclinical diagnostic spa italy penta pty limited australia johnson johnson indonesia indonesia shanghai johnson johnson limited china shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloid pty ltd australia table table caption jurisdiction subsidiary organization tibotec bvba belgium tibotec pharmaceuticals ltd ireland tibotecvirco comm belgium vania expansion snc france virco bvba belgium woelm pharma gmbh germany xianjanssen pharmaceutical ltd china table text document document typeex sequence filenameyexvtxt descriptionconsent independent accountant text exhibit consent independent accountant consent incorporation reference registration statement form file form file report date january fifth thirteenth paragraph note date february february respectively relate financial statement johnson johnson appear annual report shareholder incorporate annual report consent incorporation reference report date january relate financial statement schedule appear pricewaterhousecooper llp pricewaterhousecooper llp new york new york march text documentdocument typeexa sequence filenameyexvwatxt descriptioncertification ceo text exhibit certification chief executive officer rule securities exchange act pursuant section sarbanesoxley act william weldon certify review annual report johnson johnson registrant base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure present annual report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change registrant internal control financial reporting occur registrant recent fiscal quarter materially affect reasonably likely materially affect registrant internal control financial reporting registrant certify officer disclose base recent evaluation internal control financial reporting registrant auditor audit committee registrant board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect registrant ability record process summarize report financial information fraud material involve management employee significant role registrant internal control financial reporting william weldon william weldon chief executive officer date march text document documenttypeexb sequence filenameyexvwbtxt descriptioncertification cfo text exhibit certification chief financial officer rule securities exchange act pursuant section sarbanesoxley act robert darretta certify review annual report johnson johnson registrant base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule registrant design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare evaluate effectiveness registrant disclosure control procedure present annual report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change registrant internal control financial reporting occur registrant recent fiscal quarter materially affect reasonably likely materially affect registrant internal control financial reporting registrant certify officer disclose base recent evaluation internal control financial reporting registrant auditor audit committee registrant board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect registrant ability record process summarize report financial information fraud material involve management employee significant role registrant internal control financial reporting robert darretta robert darretta chief financial officer date march text document document typeexasequence filenameyexvwatxt descriptioncertification ceo text exhibit certification chief executive officer pursuant section sarbanesoxley act undersign william weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifies company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company william weldon william weldon chief executive officer date march certification furnish sec report form pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act text document document typeexb sequence filenameyexvwbtxt descriptioncertification cfo text exhibit certification chief financial officer pursuant section sarbanesoxley act undersign robert darretta chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifies company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company robert darretta robert darretta chief financial officer date march certification furnish sec report form pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act textdocument document typeexb sequence filenameyexvwbtxt descriptioncautionary statement text exhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company assume obligation update forwardlooke statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor include fact continue competition procrit topselle product company portfolio new competition expect cypher drugelute stent challenge company patent competitor allegation company product infringe patent party potentially affect company competitive position ability sell product question require payment past damage future royalty particular generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic version product issue introduce result substantial market share revenue loss financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action interruption computer communication system include computer virus impair company ability conduct business communicate internally customer health care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment government law regulation relate sale promotion reimbursement pricing generally government law regulation affect foreign operation include relate security law compliance trade monetary fiscal policy taxis price control regulatory approval new product license patent right include particular propose amendments hatchwaxman act implementation recently enact medicare prescription drug improvement modernization act competition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improve product important company success area business difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product significant litigation adverse company include product liability claim patent infringement claim antitrust claim health care industry come increase scrutiny government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include debarment government business product efficacy safety concern result product recall regulatory action fda foreign counterpart decline sale impact business combination include acquisition divestiture internally company externally pharmaceutical health care industry issuance new revise accounting standard american institute certify public accountant financial accounting standard board securities exchange commission foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act text document secdocument end privacyenhance message